Background: Deficiency of IL-1 receptor antagonist (DIRA) is a rare autoinflammatory disease that presents with life-threatening systemic inflammation, aseptic multifocal osteomyelitis, and pustulosis responsive to IL-1-blocking treatment. This study was performed (a) to investigate rilonacept, a long-acting IL-1 inhibitor, in maintaining anakinra-induced inflammatory remission in DIRA patients, (b) to determine doses needed to maintain remission, and (c) to evaluate the safety and pharmacokinetics of rilonacept in young children (<12 years).
Methods: Six mutation-positive DIRA patients (children, ages 3-6 years), treated with daily anakinra, were enrolled into an open-label pilot study of subcutaneous rilonacept for 24 months. Clinical symptoms and inflammatory blood parameters were measured at all visits. A loading dose (4.4 mg/kg) was administered, followed by once weekly injections (2.2 mg/kg) for 12 months. Dose escalation (4.4 mg/kg) was allowed if inflammatory remission was not maintained. Subjects in remission at 12 months continued rilonacept for an additional 12 months.
Results: Five of six patients required dose escalation for findings of micropustules. Following dose escalation, all patients were in remission on weekly rilonacept administration, with stable laboratory parameters for the entire study period of 24 months. All children are growing at normal rates and have normal heights and weights. Quality of life improved while on rilonacept. No serious adverse events were reported.
Conclusion: Rilonacept was found to maintain inflammatory remission in DIRA patients. The once weekly injection was well tolerated and correlated with increased quality of life, most likely related to the lack of daily injections.
Trial registration: ClinicalTrials.gov NCT01801449.
Funding: NIH, NIAMS, and NIAID.
Keywords: Clinical Trials; Immunology.
Conflict of interest statement
A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.Arthritis Rheum. 2008 Aug;58(8):2432-42. doi: 10.1002/art.23620. Arthritis Rheum. 2008. PMID: 18668591 Free PMC article. Clinical Trial.
Interleukin-1 inhibitors for acute gout.Cochrane Database Syst Rev. 2014 Sep 1;(9):CD009993. doi: 10.1002/14651858.CD009993.pub2. Cochrane Database Syst Rev. 2014. PMID: 25177840 Review.
Deficiency of Interleukin-1 Receptor Antagonist (DIRA): Report of the First Indian Patient and a Novel Deletion Affecting IL1RN.J Clin Immunol. 2017 Jul;37(5):445-451. doi: 10.1007/s10875-017-0399-1. Epub 2017 May 15. J Clin Immunol. 2017. PMID: 28503715 Review.
Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study.Allergy. 2012 Jul;67(7):943-50. doi: 10.1111/j.1398-9995.2012.02843.x. Epub 2012 May 15. Allergy. 2012. PMID: 22583335 Clinical Trial.
Rilonacept in the treatment of chronic inflammatory disorders.Drugs Today (Barc). 2009 Jun;45(6):423-30. doi: 10.1358/dot.2009.45.6.1378935. Drugs Today (Barc). 2009. PMID: 19649332 Review.
Cited by 4 articles
Dramatic Response of Familial Majeed Syndrome to Interleukin-1 Antagonist Therapy: Case report.Arch Rheumatol. 2019 Apr 22;34(3):352-356. doi: 10.5606/ArchRheumatol.2019.7267. eCollection 2019 Sep. Arch Rheumatol. 2019. PMID: 31598604 Free PMC article.
The Multifaceted Roles of Pyroptotic Cell Death Pathways in Cancer.Cancers (Basel). 2019 Sep 5;11(9):1313. doi: 10.3390/cancers11091313. Cancers (Basel). 2019. PMID: 31492049 Free PMC article. Review.
Deficiency of Interleukin-1 Receptor Antagonist: A Case with Late Onset Severe Inflammatory Arthritis, Nail Psoriasis with Onychomycosis and Well Responsive to Adalimumab Therapy.Case Reports Immunol. 2019 Aug 4;2019:1902817. doi: 10.1155/2019/1902817. eCollection 2019. Case Reports Immunol. 2019. PMID: 31467740 Free PMC article.
Scoping Review on Use of Drugs Targeting Interleukin 1 Pathway in DIRA and DITRA.Dermatol Ther (Heidelb). 2018 Dec;8(4):539-556. doi: 10.1007/s13555-018-0269-7. Epub 2018 Nov 3. Dermatol Ther (Heidelb). 2018. PMID: 30392030 Free PMC article. Review.